NUP214 fusion genes in acute leukemia (Review)

por ZHOU, MIN-HANG, YANG, QING-MING
Publicado 2014

A Chinese patient with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin

por Cao, Zhi-Gang, Zhou, Hong-Wei, Peng, Chao-Jin, Liu, Mo, Du, Yu, Yang, Qing-Ming
Publicado 2013

Long-term safety and efficacy of CART-20 cells in patients with refractory or relapsed B-cell non-Hodgkin lymphoma: 5-years follow-up results of the phase I and IIa trials

por Zhang, Wen-ying, Liu, Yang, Wang, Yao, Wang, Chun-meng, Yang, Qing-ming, Zhu, Hong-li, Han, Wei-dong
Publicado 2017

Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma

por Feng, Kai-chao, Guo, Ye-lei, Liu, Yang, Dai, Han-ren, Wang, Yao, Lv, Hai-yan, Huang, Jian-hua, Yang, Qing-ming, Han, Wei-dong
Publicado 2017

Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia

por Yang, Qing-Ming, Hong, Jung Yong, Ko, Young Hyeh, Lin, Shek-Ying, Au, Wing-Yan, Choi, Moon Ki, Park, Silvia, Kim, Seok Jin, Kim, Won Seog
Publicado 2014

CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial

por Wang, Yao, Chen, Meixia, Wu, Zhiqiang, Tong, Chuan, Dai, Hanren, Guo, Yelei, Liu, Yang, Huang, Jianhua, Lv, Haiyan, Luo, Can, Feng, Kai-chao, Yang, Qing-ming, Li, Xiao-lei, Han, Weidong
Publicado 2018

Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report

por Zhang, Wen-ying, Wang, Yao, Guo, Ye-lei, Dai, Han-ren, Yang, Qing-ming, Zhang, Ya-jing, Zhang, Yan, Chen, Mei-xia, Wang, Chun-meng, Feng, Kai-chao, Li, Su-xia, Liu, Yang, Shi, Feng-xia, Luo, Can, Han, Wei-dong
Publicado 2016